The AACR remains fully committed to supporting publishing operations throughout this challenging time, while still remaining flexible and supportive of the author, reviewer, and editor communities that we serve. If you have any questions or concerns, please reach out to a member of the AACR publishing staff.
Please visit the COVID-19 & Cancer Resource Center where COVID-related content is freely available.
News from Cancer Discovery
- Dual-Targeting Approach for CD40 and 4-1BB
GEN1042, a bispecific antibody, is safe, shows signs of antitumor activity. - Immunotherapy First for BRAF-Mutant Melanoma
Dramatic improvement in 2-year OS with checkpoint inhibitor combo brings DREAMseq trial to early end. - As Maintenance Therapy, Olaparib's Benefits Continue
5-year follow-up shows significant increase in PFS, no new safety concerns.
Advertisement
Trending - Altmetric
- Fasting-mimicking diet is safe and reshapes metabolism and antitumor immunity in cancer patientsLast mentioned on Mon Nov 29 2021
- Tumor genomic profiling guides metastatic gastric cancer patients to targeted treatment: The VIKTORY Umbrella TrialLast mentioned on Wed Nov 24 2021
- AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung CancerLast mentioned on Wed Nov 24 2021
- Implementing a functional precision medicine tumor board for acute myeloid leukemiaLast mentioned on Fri Nov 26 2021
- EP300 selectively controls the enhancer landscape of MYCN-amplified neuroblastomaLast mentioned on Sat Nov 27 2021
- See more
